Jefferies Cuts Numbers on ISIS Pharmaceuticals (ISIS) Despite Panel Backing

October 19, 2012 8:47 AM EDT Send to a Friend
Get Alerts ISIS Hot Sheet
Price: $51.34 +0.79%

Rating Summary:
    6 Buy, 7 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 28 | New: 35
Trade ISIS Now!
Join SI Premium – FREE
Jefferies trimmed its price target on ISIS Pharmaceuticals (NASDAQ: ISIS) from $10 to $8 and kept its Underperform rating despite FDA panel backing of Kynamro.

"While Kynamro commercial potential is low, its approval would validate ISIS' antisense technology platform. However, given numerous side effects of Kynamro Tx in clinical/preclinical testing, we view long-term safety of antisense oligo products given systemically as unclear/yet-to-be determined," analyst Eun Yang comments.

FY13 EPS goes down from ($0.96) to ($1.12).

For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.

Shares of ISIS Pharmaceuticals closed at $9.62 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment